BioVie Analyst Ratings
ThinkEquity Initiates Coverage On BioVie With Buy Rating, Announces Price Target of $3
BioVie Analyst Ratings
Oppenheimer Adjusts BioVie Price Target to $5 From $12, Maintains Outperform Rating
BioVie (BIVI) Gets a Buy From Oppenheimer
Analysts Conflicted on These Consumer Goods Names: Yum! Brands (YUM) and BioVie (BIVI)
Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Altria Group (MO), Keurig Dr Pepper (KDP) and BioVie (BIVI)
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target
BioVie Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target
BioVie Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Pfizer (PFE) and BioVie (BIVI)
Oppenheimer Sticks to Their Buy Rating for BioVie (BIVI)
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Seagen (SGEN) and BioVie (BIVI)
Analysts Offer Insights on Healthcare Companies: BioVie (BIVI) and Monopar Therapeutics Inc (MNPR)
BioVie Analyst Ratings